Niagen Bioscience (NAGE) Amortization of Deferred Charges (2019 - 2024)
Niagen Bioscience's (NAGE) quarterly Amortization of Deferred Charges came in at $164000.0 in Q3 2024, down 6.82% year-on-year from $176000.0 in Q4 2023, and up 0.61% on a QoQ basis from $163000.0 in Q2 2024.
Niagen Bioscience (NAGE) Amortization of Deferred Charges (2019 - 2024) Analysis & Trends
Niagen Bioscience (NAGE) has 5 years of Amortization of Deferred Charges data on file, last reported at $164000.0 in Q3 2024.
- On a quarterly basis, Amortization of Deferred Charges fell 6.82% year-over-year to $164000.0 in Q3 2024; TTM through Sep 2024 was $658000.0, a 7.45% decrease from a year earlier, with the FY2023 full-year figure at $677000.0, down 18.34% from the prior year.
- Amortization of Deferred Charges for Q3 2024 stood at $164000.0, up from $163000.0 in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for NAGE reached as high as $299000.0 in Q1 2022 and fell as low as $126000.0 in Q1 2021.
- Historically, Amortization of Deferred Charges has averaged $167866.7 across 4 years, with a median of $169000.0 in 2022.
- Across the five-year window, Amortization of Deferred Charges jumped 137.3% in 2022 and slumped 42.81% in 2023, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $126000.0 in 2021, then soared by 51.59% to $191000.0 in 2022, then fell by 17.8% to $157000.0 in 2023, then rose by 4.46% to $164000.0 in 2024.
- Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $164000.0 in Q3 2024, $163000.0 in Q2 2024, and $174000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Niagen Bioscience | 258.53 Mn | 191.98 Mn | 19.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 164,000.00 |
| Sep 30, 2024 | 164,000.00 |
| Jun 30, 2024 | 163,000.00 |
| Jun 30, 2024 | 163,000.00 |
| Mar 31, 2024 | 174,000.00 |
| Mar 31, 2024 | 174,000.00 |
| Dec 31, 2023 | 157,000.00 |
| Dec 31, 2023 | 157,000.00 |
| Sep 30, 2023 | 176,000.00 |
| Sep 30, 2023 | 176,000.00 |
| Jun 30, 2023 | 173,000.00 |
| Jun 30, 2023 | 173,000.00 |
| Mar 31, 2023 | 171,000.00 |
| Mar 31, 2023 | 171,000.00 |
| Dec 31, 2022 | 191,000.00 |
| Dec 31, 2022 | 191,000.00 |
| Sep 30, 2022 | 170,000.00 |
| Sep 30, 2022 | 170,000.00 |
| Jun 30, 2022 | 169,000.00 |
| Jun 30, 2022 | 169,000.00 |